Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination of five pharmacological agents—acetylcholine, sodium nitroprusside, angiotensin II, norepinephrine, and phentolamine—is used as a set of investigational probes in mechanistic clinical research to evaluate distinct vascular function pathways. Acetylcholine is administered to assess endothelial-dependent vasodilation via nitric oxide signaling, while sodium nitroprusside evaluates endothelial-independent vasodilation. Angiotensin II and norepinephrine are used to probe vasoconstrictive pathways (the renin-angiotensin and adrenergic systems, respectively), and phentolamine acts as an alpha-adrenergic blocker to isolate specific vascular responses. This combination is primarily utilized in studies led by Russell Richardson to characterize vascular adaptations in aging and cardiovascular conditions such as hypertension and chronic obstructive pulmonary disease (COPD). These agents are well-known generic small molecules and peptides used purely as research tools rather than as a single therapeutic drug product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetylcholine + sodium nitroprusside + angiotensin II + norepinephrine + phentolamine.